Ms Julie Fereday
Honorary Senior Fellow
The Sir Peter MacCallum Department of Oncology
144 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma
DOI: 10.1038/s41467-026-71134-32026
Journal article
Using Polygenic Risk Scores to Refine Risk and Outcomes in High-grade Serous Ovarian Cancer in Australia.
DOI: 10.1158/1055-9965.EPI-25-18822026
Other
Supplementary Tables 1-16 from Using Polygenic Risk Scores to Refine Risk and Outcomes in High-grade Serous Ovarian Cancer in Australia
DOI: 10.1158/1055-9965.340411872026
Other
Supplementary Figure 12 from Using Polygenic Risk Scores to Refine Risk and Outcomes in High-grade Serous Ovarian Cancer in Australia
DOI: 10.1158/1055-9965.340412142026
Other
Supplementary Figure 5 from Using Polygenic Risk Scores to Refine Risk and Outcomes in High-grade Serous Ovarian Cancer in Australia
DOI: 10.1158/1055-9965.340412022024
Journal article
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
DOI: 10.1186/s12943-024-02048-12015
Journal article
Whole-genome characterization of chemoresistant ovarian cancer
DOI: 10.1038/nature14410
RECENT SCHOLARLY WORKS
2026
Other
Supplementary Figure 10 from Using Polygenic Risk Scores to Refine Risk and Outcomes in High-grade Serous Ovarian Cancer in Australia
DOI: 10.1158/1055-9965.340412202026
Other
Supplementary Figure 11 from Using Polygenic Risk Scores to Refine Risk and Outcomes in High-grade Serous Ovarian Cancer in Australia
DOI: 10.1158/1055-9965.340412172026
Other
Supplementary Figure 3 from Using Polygenic Risk Scores to Refine Risk and Outcomes in High-grade Serous Ovarian Cancer in Australia
DOI: 10.1158/1055-9965.340412082026
Other
Supplementary Figure 6 from Using Polygenic Risk Scores to Refine Risk and Outcomes in High-grade Serous Ovarian Cancer in Australia
DOI: 10.1158/1055-9965.340411992026
Other
Supplementary Figure 7 from Using Polygenic Risk Scores to Refine Risk and Outcomes in High-grade Serous Ovarian Cancer in Australia
DOI: 10.1158/1055-9965.34041196